Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2021-09-27 Biomarkers

    Multiple variables affect plasma biomarkers of amyloid pathology and neurodegeneration among CU in the general population.

  2. The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Clinica chimica acta; international journal of clinical chemistry 2021-05-17 Biomarkers

    The PrecivityAD™ assays are precise, accurate, sensitive, and linear over a wide analytical range, free from significant interferences, and suitable for use in the clinical laboratory.

  3. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's research & therapy 2021-03-25 Biomarkers

    Plasma NfL indicates neurodegeneration while plasma p-tau181 levels can serve as a biomarker of cerebral AD pathology and cognitive decline.

  4. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular neurodegeneration 2021-02-19 Biomarkers

    Four fluid-based biomarkers have been developed into diagnostic tests for Alzheimer's disease (AD) pathology: the ratio of 42 to 40 amino acid-long amyloid β, a marker of plaque pathology; total-tau and phosphorylated tau, markers of AD-related changes in tau metabolism and secretion; and neurofilament light, a marker of neurodegeneration.

  5. Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurology 2021-02-10 Treatments

    Reduced amyloid was observed in self-identified NHB participants who passed initial eligibility criteria for the A4 study.

  6. Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmaceuticals (Basel, Switzerland) 2021-01-30 Brain scans and imaging

    Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology.

  7. Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Translational psychiatry 2021-01-26 Brain scans and imaging

    Mild behavioral impairment (MBI) is suggested as risk marker for neurodegenerative diseases, such as Alzheimer's disease (AD).

  8. Identification of Cathepsin D as a Plasma Biomarker for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cells 2021-01-12 Biomarkers

    Although Alzheimer's disease (AD) is the most common neurodegenerative disease, there are still no drugs available to treat or prevent AD effectively.

  9. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain : a journal of neurology 2020-12-01 Brain scans and imaging

    Mean SUVRs were calculated for progressive supranuclear palsy, corticobasal degeneration, and neurofibrillary tangle Braak stage regions of interest, and these values were compared to SUVRs derived from young, non-autopsy, cognitively normal controls used as a standard for tau negativity.

  10. Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's research & therapy 2020-10-02 Biomarkers

    These results indicate that an increase in the baseline level of amyloid peptides, which are associated with an increase in p-tau (181), may be a biological characteristic and possibly a risk factor for AD.

  11. Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Annals of neurology 2020-09-25 Biomarkers

    Plasma NT1 tau was specifically elevated in AD, but not in non-AD dementia compared with controls, whereas NfL was increased in both AD and non-AD dementias.

  12. Cerebrovascular medin is associated with Alzheimer's disease and vascular dementia

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2020-08-25 Vascular contributions

    Arteriole medin was higher in those with AD, VaD, or combined AD/VaD versus ND (P < .05), and correlated with tangle, plaque, and WML, but not CAA or CoW atherosclerosis.

  13. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Acta neuropathologica 2020-08-09 Brain scans and imaging

    Fixed tissue sections of frontal cortex and caudate from 10 of the AD cases were processed for microscopy using fluorescent derivatives of flutemetamol (cyano-flutemetamol) and PiB (cyano-PiB) and compared to Aβ immunohistochemistry and pan-amyloid (X-34) histology.

  14. Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of neuropathology and experimental neurology 2020-03-01 Brain tissue and pathology

    Distinct neuronal and glial tau pathologies define corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP).

  15. Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in aging neuroscience 2020-01-29 Biomarkers

    An inverse association may exist between cancers and neurodegenerative diseases, although convenient biomarkers for verifying this inverse association are lacking.

  16. Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01 Biomarkers

    MDS-OAβ to measure plasma Aβ oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.

  17. Regional Amyloid Accumulation and White Matter Integrity in Cognitively Normal Individuals

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2020 Brain scans and imaging

    Our results indicated that higher global Aβ-SUVR was associated with higher mean diffusivity (MD) in the entire CN group (p = 0.023), and with both higher MD (p = 0.015) and lower fractional anisotropy (FA) (p = 0.026) in APOEɛ4 carriers.

  18. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2019-05-14 Brain scans and imaging

    Against combined Bielschowsky silver staining and immunohistochemistry histopathological scores, statistical parametric mapping had 96% sensitivity, 96% specificity, and 95% accuracy, whereas magnetic resonance-less CapAIBL standardized uptake value ratioWhole Cerebellum had 94% sensitivity, 96% specificity, and 95% accuracy.

  19. Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. NeuroImage 2018-08-18 Brain scans and imaging

    Using the calibration images, there was a very strong agreement, and very little bias between the centiloid values computed using CapAIBL and those computed using the standard method with R2 > 0.97 across all tracers.

  20. Topographic staging of tau positron emission tomography images

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2018-02-14 Brain scans and imaging

    All three schemes estimated stages that were significantly associated with amyloid status and when dichotomized to tau positive or negative were 90% to 94% concordant in the populations identified.

  21. Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2017-11-23 Tau biomarkers

    CSF Aβ1-42 was higher in the T2DM group than the nondiabetic group.

  22. Emerging concepts in sporadic cerebral amyloid angiopathy

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain : a journal of neurology 2017-07-01 Vascular contributions

    Sporadic cerebral amyloid angiopathy is a common, well-defined small vessel disease and a largely untreatable cause of intracerebral haemorrhage and contributor to age-related cognitive decline.

  23. Approach to atypical Alzheimer's disease and case studies of the major subtypes

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. CNS spectrums 2017-02-15 Risk factors

    Alzheimer's disease (AD) has long been recognized as a heterogeneous illness, with a common clinical presentation of progressive amnesia and less common "atypical" clinical presentations, including syndromes dominated by visual, aphasic, "frontal," or apraxic symptoms.

  24. Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017-02-11 Tau biomarkers

    Nineteen nonamnestic autopsied cases with relevant CSF values were included.

  25. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01 Down syndrome and Alzheimer's

    Overexpression of the amyloid precursor protein (APP) gene on chromosome 21 in Down syndrome (DS) has been linked to increased brain amyloid levels and early-onset Alzheimer's disease (AD).

From across this topic

10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics